Travere Therapeutics Dividend
Dividend criteria checks 0/6
Travere Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.9% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | -US$4.94 |
| Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop
Apr 20
Travere Therapeutics: Restructuring Away From Disaster
Jan 30Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jan 22Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)
Aug 08Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Jun 09It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks
May 05Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 16Travere Therapeutics' FDA target action date for nephropathy treatment extended
Oct 13Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Oct 06Travere Therapeutics: Changes In The Risk-Reward Assessment
Sep 29Travere, CSL kidney disease drug sparsentan gets review in EU
Aug 22Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M
Aug 04Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'
Jul 14Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Jun 19Travere Therapeutics: Strong Sell, Ticking Time Bomb, We Are Passing
Apr 11Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 07Travere Therapeutics: Tarpeyo's Approval Is Good News
Jan 31Does Travere Therapeutics (NASDAQ:TVTX) Have A Healthy Balance Sheet?
Oct 07Regulatory Uncertainty Holding Travere Therapeutics Down Despite PROTECT Study Success
Aug 30Travere: Setback Presents Cautious Opportunity
Jul 18Does Travere Therapeutics (NASDAQ:TVTX) Have A Healthy Balance Sheet?
Jul 09Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if TVTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TVTX's dividend payments have been increasing.
Dividend Yield vs Market
| Travere Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (TVTX) | n/a |
| Market Bottom 25% (US) | 1.6% |
| Market Top 25% (US) | 4.8% |
| Industry Average (Biotechs) | 2.9% |
| Analyst forecast in 3 Years (TVTX) | 0% |
Notable Dividend: Unable to evaluate TVTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TVTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate TVTX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TVTX has not reported any payouts.